['type 2 diabetes mellitus']
['sar342434', 'humalog', 'insulin glargine hoe901']

        Inclusion criteria:

          -  Participants with T2DM diagnosed for at least 12 months and treated with insulin
             glargine and Humalog®/Liprolog® or NovoLog®/NovoRapid® (at least 3 times daily, before
             each meal) in the 6 months prior to the screening visit.

          -  Signed written informed consent.

        Exclusion criteria:

          -  At screening visit, age under legal age of adulthood.

          -  HbA1c <6.5% or >10.0% at screening.

          -  Diabetes other than T2DM.

          -  Pregnancy and lactation.

          -  Women of childbearing potential not protected by highly effective contraceptive method
             of birth control.

          -  Use of insulin pump in the 6 months before screening visit.

          -  Use of insulin other than insulin glargine and Humalog or NovoLog/NovoRapid in the 6
             months prior to screening visit. Liprolog® is an European Union (EU) approved insulin
             lispro and is allowed in those countries where it is marketed.

          -  Use of Humalog/Liprolog or Novolog/NovoRapid less than 3 times daily, before each
             meal.

          -  Use of non-injectable peptides (eg, Glucagon-like peptide-1 (GLP-1) receptor-agonists
             or other peptides) in the 6 months prior to screening visit.

          -  Body mass index (BMI) >=40kg/m² at screening visit.

          -  Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment, or injectable drugs) during the study period.

          -  The above information is not intended to contain all considerations relevant to a
             participant's potential participation in a clinical trial
      